Taha Afzal
About Taha Afzal
Taha Afzal is the Associate Director of US Commercial Cell Therapy Finance at Bristol Myers Squibb, with extensive experience in finance and treasury roles within the company and a background in accounting from Deloitte and Haines Watts.
Company
Taha Afzal currently works at Bristol Myers Squibb, a notable biopharmaceutical company headquartered in New Jersey, United States. He has been with the company in various capacities and locations, from Jeddah, Saudi Arabia, to New Jersey. His roles at the organization have spanned across different functions, such as Technical Accounting, International Treasury, and Commercial Immunoscience Finance.
Title
Taha Afzal holds the position of Associate Director, US Commercial Cell Therapy Finance, at Bristol Myers Squibb. In this role, he oversees the financial management of the company's commercial cell therapy operations in the United States.
Education and Expertise
Taha Afzal has an extensive educational background in finance and accounting. He earned a Master of Business Administration (M.B.A.) from the University of Warwick - Warwick Business School, and a BSc (Hons) in Applied Accounting from Oxford Brookes University. In addition, he is an ACCA-certified professional, having studied Professional Accountancy at ACCA.
Professional Background
Taha Afzal's career spans over two decades, featuring roles in diverse geographical locations and industries. His work experience includes seven years at Deloitte as an Audit Manager in Jeddah, Saudi Arabia. He also worked for two years as an Assistant Management Accountant at Haines Watts in London, United Kingdom. At Bristol Myers Squibb, he has served in multiple roles, including Finance Manager for US Commercial Immunoscience and Manager of Technical Accounting for the USHQ Finance.
Achievements
During his tenure at Bristol Myers Squibb, Taha Afzal has made significant contributions, including leading the financial integration of a newly acquired cell therapy company into US commercial operations. He implemented a new financial planning and analysis system that enhanced forecasting accuracy by 15%. His financial strategy efforts also supported the launch of a new cell therapy product, contributing to a 20% market share increase. In 2021, he received the 'Excellence in Financial Leadership' award for his outstanding contributions. Additionally, he has presented at the 2022 Annual Conference on Cell Therapy Finance and mentors junior finance professionals within the company.